The Status Quo
Drugs are developed using the law of averages, so in order to reach the largest market possible, they address disease symptoms for large average patient populations. As a result, drugs often fail individual patients. Two-thirds of patients who are prescribed drugs don’t respond adequately to the treatment*, resulting in billions of dollars wasted on ineffective therapies and health care, leading to an unprecedented burden on patients, hospitals and payers.
Today’s approach forces people to follow a "failure first strategy" by trying drug after drug until they finally find something that works—making their treatment a painful and dangerous process of trial and error.
The situation is particularly dire in complex diseases which are governed by weak genetic links and strong environmental factors. In some cases, such as autoimmune diseases, drug response rates are falling below 20%.
*"Adequate treatment response is defined as ACR50 response, or a >50% improvement of disease condition.
66% of patients who are prescribed drugs don't respond adequately to the treatment.*
Doubling the drug response rate for anti-TNF therapies.
Our platform allows for blood and tissue tests taken at a routine doctor’s visit, to predict if your drug response will be adequate or not. As a result, you will only be prescribed the most likely effective treatment, resulting in faster recovery and reducing wasted health care costs.
For example in Rheumatoid Arthritis, if our test was ordered before prescribing 100% of all anti-TNF drugs in the United States, it would double drug response rates from 35% up to 67% while saving over $4.7 billion by avoiding unnecessary treatment and health care costs, and ensuring patients receive the best care from day one.